Thyroid transcription factor 1 in pulmonary adenocarcinoma

Grant Stenhouse, N. Fyfe, George King, Andrea .d. Chapman, K.m. Kerr

    Research output: Contribution to journalArticle

    118 Citations (Scopus)

    Abstract

    Aims: To discover whether variations in thyroid transcription factor 1 (TTF-1) staining in different subtypes and patterns of pulmonary adenocarcinoma are related to the putative origin of the tumour. In addition, to confirm the specificity of TTF-1 for pulmonary ( as opposed to other sites) adenocarcinoma, to examine the possible prognostic relevance of TTF-1 positivity in lung cancer, and to review this laboratory's experience of TTF-1 in diagnostic practice.

    Materials/ Methods: In total, 128 primary lung adenocarcinomas, 106 primary non-pulmonary adenocarcinomas, and 37 pulmonary non-adenocarcinoma tumours were studied. In addition, 100 cases where TTF-1 was used in routine surgical pathology practice were investigated. Immunoperoxidase staining was performed on formalin fixed, paraffin wax embedded sections using anti-TTF-1 antibody. Staining was evaluated semiquantitatively using the frequency and intensity of nuclear positivity.

    Results: None of the 106 non-pulmonary adenocarcinomas expressed TTF-1 and only three of the 37 nonadenocarcinoma lung cancers, all neuroendocrine carcinomas, were positive. Of the pulmonary adenocarcinomas, 75% were strongly positive for TTF-1. Mucinous ( two of six) and poorly differentiated adenocarcinomas ( four of 10) were less likely to stain. Of the peripheral adenocarcinomas, 33 of 37 were positive, whereas only seven of 14 of those of bronchial origin stained strongly. Atypical adenomatous hyperplasia strongly expressed TTF-1. No "false positives'' were encountered in the 100 routine diagnostic cases.

    Conclusion: Positive TTF-1 staining is useful in the differential diagnosis of pulmonary adenocarcinomas. TTF-1 may be a lineage marker for tumours arising from the peripheral airway or alveolar epithelium and has no prognostic relevance.

    Original languageEnglish
    Pages (from-to)383-387
    Number of pages4
    JournalJournal of Clinical Pathology
    Volume57
    Issue number4
    DOIs
    Publication statusPublished - 2004

    Keywords

    • SMALL-CELL CARCINOMAS
    • FACTOR-I
    • LUNG-CANCER
    • NEUROENDOCRINE TUMORS
    • SURFACTANT PROTEINS
    • EXPRESSION
    • CYTOKERATIN-20
    • TTF-1
    • MORPHOGENESIS
    • FETAL

    Cite this

    Thyroid transcription factor 1 in pulmonary adenocarcinoma. / Stenhouse, Grant; Fyfe, N.; King, George; Chapman, Andrea .d.; Kerr, K.m.

    In: Journal of Clinical Pathology, Vol. 57, No. 4, 2004, p. 383-387.

    Research output: Contribution to journalArticle

    Stenhouse, Grant ; Fyfe, N. ; King, George ; Chapman, Andrea .d. ; Kerr, K.m. / Thyroid transcription factor 1 in pulmonary adenocarcinoma. In: Journal of Clinical Pathology. 2004 ; Vol. 57, No. 4. pp. 383-387.
    @article{bd0f2b9a6005453ba5ef441e8ec14d08,
    title = "Thyroid transcription factor 1 in pulmonary adenocarcinoma",
    abstract = "Aims: To discover whether variations in thyroid transcription factor 1 (TTF-1) staining in different subtypes and patterns of pulmonary adenocarcinoma are related to the putative origin of the tumour. In addition, to confirm the specificity of TTF-1 for pulmonary ( as opposed to other sites) adenocarcinoma, to examine the possible prognostic relevance of TTF-1 positivity in lung cancer, and to review this laboratory's experience of TTF-1 in diagnostic practice.Materials/ Methods: In total, 128 primary lung adenocarcinomas, 106 primary non-pulmonary adenocarcinomas, and 37 pulmonary non-adenocarcinoma tumours were studied. In addition, 100 cases where TTF-1 was used in routine surgical pathology practice were investigated. Immunoperoxidase staining was performed on formalin fixed, paraffin wax embedded sections using anti-TTF-1 antibody. Staining was evaluated semiquantitatively using the frequency and intensity of nuclear positivity.Results: None of the 106 non-pulmonary adenocarcinomas expressed TTF-1 and only three of the 37 nonadenocarcinoma lung cancers, all neuroendocrine carcinomas, were positive. Of the pulmonary adenocarcinomas, 75{\%} were strongly positive for TTF-1. Mucinous ( two of six) and poorly differentiated adenocarcinomas ( four of 10) were less likely to stain. Of the peripheral adenocarcinomas, 33 of 37 were positive, whereas only seven of 14 of those of bronchial origin stained strongly. Atypical adenomatous hyperplasia strongly expressed TTF-1. No {"}false positives'' were encountered in the 100 routine diagnostic cases.Conclusion: Positive TTF-1 staining is useful in the differential diagnosis of pulmonary adenocarcinomas. TTF-1 may be a lineage marker for tumours arising from the peripheral airway or alveolar epithelium and has no prognostic relevance.",
    keywords = "SMALL-CELL CARCINOMAS, FACTOR-I, LUNG-CANCER, NEUROENDOCRINE TUMORS, SURFACTANT PROTEINS, EXPRESSION, CYTOKERATIN-20, TTF-1, MORPHOGENESIS, FETAL",
    author = "Grant Stenhouse and N. Fyfe and George King and Chapman, {Andrea .d.} and K.m. Kerr",
    year = "2004",
    doi = "10.1136/jcp.2003.007138",
    language = "English",
    volume = "57",
    pages = "383--387",
    journal = "Journal of Clinical Pathology",
    issn = "0021-9746",
    publisher = "BMJ Publishing Group",
    number = "4",

    }

    TY - JOUR

    T1 - Thyroid transcription factor 1 in pulmonary adenocarcinoma

    AU - Stenhouse, Grant

    AU - Fyfe, N.

    AU - King, George

    AU - Chapman, Andrea .d.

    AU - Kerr, K.m.

    PY - 2004

    Y1 - 2004

    N2 - Aims: To discover whether variations in thyroid transcription factor 1 (TTF-1) staining in different subtypes and patterns of pulmonary adenocarcinoma are related to the putative origin of the tumour. In addition, to confirm the specificity of TTF-1 for pulmonary ( as opposed to other sites) adenocarcinoma, to examine the possible prognostic relevance of TTF-1 positivity in lung cancer, and to review this laboratory's experience of TTF-1 in diagnostic practice.Materials/ Methods: In total, 128 primary lung adenocarcinomas, 106 primary non-pulmonary adenocarcinomas, and 37 pulmonary non-adenocarcinoma tumours were studied. In addition, 100 cases where TTF-1 was used in routine surgical pathology practice were investigated. Immunoperoxidase staining was performed on formalin fixed, paraffin wax embedded sections using anti-TTF-1 antibody. Staining was evaluated semiquantitatively using the frequency and intensity of nuclear positivity.Results: None of the 106 non-pulmonary adenocarcinomas expressed TTF-1 and only three of the 37 nonadenocarcinoma lung cancers, all neuroendocrine carcinomas, were positive. Of the pulmonary adenocarcinomas, 75% were strongly positive for TTF-1. Mucinous ( two of six) and poorly differentiated adenocarcinomas ( four of 10) were less likely to stain. Of the peripheral adenocarcinomas, 33 of 37 were positive, whereas only seven of 14 of those of bronchial origin stained strongly. Atypical adenomatous hyperplasia strongly expressed TTF-1. No "false positives'' were encountered in the 100 routine diagnostic cases.Conclusion: Positive TTF-1 staining is useful in the differential diagnosis of pulmonary adenocarcinomas. TTF-1 may be a lineage marker for tumours arising from the peripheral airway or alveolar epithelium and has no prognostic relevance.

    AB - Aims: To discover whether variations in thyroid transcription factor 1 (TTF-1) staining in different subtypes and patterns of pulmonary adenocarcinoma are related to the putative origin of the tumour. In addition, to confirm the specificity of TTF-1 for pulmonary ( as opposed to other sites) adenocarcinoma, to examine the possible prognostic relevance of TTF-1 positivity in lung cancer, and to review this laboratory's experience of TTF-1 in diagnostic practice.Materials/ Methods: In total, 128 primary lung adenocarcinomas, 106 primary non-pulmonary adenocarcinomas, and 37 pulmonary non-adenocarcinoma tumours were studied. In addition, 100 cases where TTF-1 was used in routine surgical pathology practice were investigated. Immunoperoxidase staining was performed on formalin fixed, paraffin wax embedded sections using anti-TTF-1 antibody. Staining was evaluated semiquantitatively using the frequency and intensity of nuclear positivity.Results: None of the 106 non-pulmonary adenocarcinomas expressed TTF-1 and only three of the 37 nonadenocarcinoma lung cancers, all neuroendocrine carcinomas, were positive. Of the pulmonary adenocarcinomas, 75% were strongly positive for TTF-1. Mucinous ( two of six) and poorly differentiated adenocarcinomas ( four of 10) were less likely to stain. Of the peripheral adenocarcinomas, 33 of 37 were positive, whereas only seven of 14 of those of bronchial origin stained strongly. Atypical adenomatous hyperplasia strongly expressed TTF-1. No "false positives'' were encountered in the 100 routine diagnostic cases.Conclusion: Positive TTF-1 staining is useful in the differential diagnosis of pulmonary adenocarcinomas. TTF-1 may be a lineage marker for tumours arising from the peripheral airway or alveolar epithelium and has no prognostic relevance.

    KW - SMALL-CELL CARCINOMAS

    KW - FACTOR-I

    KW - LUNG-CANCER

    KW - NEUROENDOCRINE TUMORS

    KW - SURFACTANT PROTEINS

    KW - EXPRESSION

    KW - CYTOKERATIN-20

    KW - TTF-1

    KW - MORPHOGENESIS

    KW - FETAL

    U2 - 10.1136/jcp.2003.007138

    DO - 10.1136/jcp.2003.007138

    M3 - Article

    VL - 57

    SP - 383

    EP - 387

    JO - Journal of Clinical Pathology

    JF - Journal of Clinical Pathology

    SN - 0021-9746

    IS - 4

    ER -